期刊
INDIAN PEDIATRICS
卷 60, 期 7, 页码 571-574出版社
SPRINGER INDIA
DOI: 10.1007/s13312-023-2937-7
关键词
-
类别
A recent study compared the efficacy of methylprednisolone and intravenous immunoglobulin for pediatric inflammatory multisystem syndrome associated with COVID-19. The study revealed promising results, providing clinicians with new treatment options.
Welzel, et al. [1] recently published a randomized controlled trial (RCT) comparing the efficacy of methylprednisolone (MP) with intravenous immunoglobulin (IVIg) for COVID-19 associated pediatric inflammatory multisystem syndrome, also referred to as COVID-19 associated multisystem inflammatory syndrome in children (MIS-C). This study was necessitated by the helplessness associated with the condition, in the face of the COVID pandemic, coupled with the ray of hope offered by these medications, documented through physician experiences and observational studies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据